748 related articles for article (PubMed ID: 29980822)
1. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
2. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
[TBL] [Abstract][Full Text] [Related]
3. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
5. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
[TBL] [Abstract][Full Text] [Related]
6. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
7. Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.
Tonstad S; Holme I; Tønnesen P
Nicotine Tob Res; 2011 Jan; 13(1):1-6. PubMed ID: 21041839
[TBL] [Abstract][Full Text] [Related]
8. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
Maggio SE; Saunders MA; Baxter TA; Nixon K; Prendergast MA; Zheng G; Crooks P; Dwoskin LP; Slack RD; Newman AH; Bell RL; Bardo MT
Psychopharmacology (Berl); 2018 May; 235(5):1439-1453. PubMed ID: 29455292
[TBL] [Abstract][Full Text] [Related]
9. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
10. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
McCaul ME; Wand GS; Kuwabara H; Dannals RF; Wong D; Xu X
Nicotine Tob Res; 2020 May; 22(6):892-899. PubMed ID: 31096265
[TBL] [Abstract][Full Text] [Related]
11. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
Cohen C; Bergis OE; Galli F; Lochead AW; Jegham S; Biton B; Leonardon J; Avenet P; Sgard F; Besnard F; Graham D; Coste A; Oblin A; Curet O; Voltz C; Gardes A; Caille D; Perrault G; George P; Soubrie P; Scatton B
J Pharmacol Exp Ther; 2003 Jul; 306(1):407-20. PubMed ID: 12682217
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination.
Anderson DJ; Malysz J; Grønlien JH; El Kouhen R; Håkerud M; Wetterstrand C; Briggs CA; Gopalakrishnan M
Biochem Pharmacol; 2009 Oct; 78(7):844-51. PubMed ID: 19555668
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic receptor antagonists as treatments for nicotine abuse.
Crooks PA; Bardo MT; Dwoskin LP
Adv Pharmacol; 2014; 69():513-51. PubMed ID: 24484986
[TBL] [Abstract][Full Text] [Related]
15. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Ortiz NC; O'Neill HC; Marks MJ; Grady SR
Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
[TBL] [Abstract][Full Text] [Related]
16. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
17. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of varenicline for smoking cessation.
Hays JT; Ebbert JO; Sood A
Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.
Marks MJ; Wageman CR; Grady SR; Gopalakrishnan M; Briggs CA
Biochem Pharmacol; 2009 Oct; 78(7):795-802. PubMed ID: 19481067
[TBL] [Abstract][Full Text] [Related]
20. Anti-smoking drugs cytisine and varenicline reduce cardiac reperfusion injury in rat model of myocardial ischemia.
Shaykhutdinova ER; Severyukhina MS; Kholoshenko IV; Gondarenko EA; Shelukhina IV; Kryukova EV; Ismailova AM; Sadovnikova ES; Dyachenko IA; Murashev AN; Tsetlin VI; Utkin YN
Biochimie; 2024 Jan; 216():108-119. PubMed ID: 37871826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
